逍遥散联合α干扰素治疗HBeAg阳性慢性乙型肝炎的临床观察  

Treatment of HBeAg Positive Chronic Hepatitis B by Xiaoyao Powder Combined with Interferon-α: a Clinical Observation

作　　者：梁惠卿[1] 唐金模[1] 吴春城[1] 陈少东[2] 

机构地区：[1]福建省厦门市中医院肝病中心,福建厦门361009 [2]厦门大学医学院中医系,福建厦门361005

出　　处：《中国中西医结合杂志》2014年第6期666-670,共5页Chinese Journal of Integrated Traditional and Western Medicine

基　　金：福建省卫生厅青年科研课题基金资助项目(No.2012-2-105)

摘　　要：目的研究逍遥散联合α干扰素(interferon-alpha,IFN-α)治疗HBeAg阳性慢性乙型肝炎疗效及对生活质量的影响。方法 193例经肝穿刺活检证实的HBeAg阳性慢性乙型肝炎患者,按照随机数字表法分为单药治疗组(94例)和联合治疗组(99例),单药治疗组给予IFN-α1b,50μg/次,皮下注射,每周3次;联合治疗组在单药治疗组的基础上,配伍逍遥散口服,两组疗程均为24周。通过评价两组ALT复常率、HBeAg阴转率、HBeAg转换率、HBV DNA阴转率、完全应答率、部分应答率以及症状积分变化等观察逍遥散联合IFN-α疗效;采用慢性肝病问卷(chronic liver disease questionnaire,CLDQ)评分进行生活质量评定;观察两组患者的不良反应发生率。结果联合治疗组在ALT复常率、HBeAg阴转率、HBV DNA阴转率、完全应答率、部分应答率、中医症状积分、中医症状总有效率、CLDQ评分和不良反应发生率方面均优于单药治疗组(P<0.05,P<0.01)。结论逍遥散可提高IFN-α治疗HBeAg阳性慢性乙型肝炎的中医症状疗效、抗病毒疗效,改善生活质量,减少IFN-α不良反应。Objective To study the efficacy of Xiaoyao Powder （XYP） combined with interferon alpha （IFN-α） in treating HBeAg positive chronic hepatitis B （CHB） patients and the effect on their quality of life （QOL）. Methods Totally 193 patients with HBeAg-positive CHB confirmed by liver biopsy ware randomly assigned to 2 groups, Group A （94 cases） and Group B （99 cases）. IFN-α1b was subcutaneously injected to patients in Group A at the dose of 50μg, thrice per week. Those in Group B additionally took XYP. The therapeutic course for all was 24 weeks. Clinical efficacy was observed by assessing ALT restoration rate, HBeAg negative rate, HBeAg conversion rate, HBV DNA negative rate, complete response rate, partial response rate, and symptoms integral. The evaluation of QOL was performed by using chronic liver disease questionnaire （CLDQ） score. Adverse reaction occurrence rate was observed in the two groups. Results Better effects were obtained in Group A on ALT restoration rate, HBeAg negative rate, HBV DNA negative rate, complete response rate, partial response rate, TCM symptoms integral, the total effective rate of TCM sysmptoms, CLDQ score, and adverse reaction rates, showing statistical difference when compared with Group B （P 〈0.05, P 〈0.01 ）. Conclusion XYP could elevate the efficacy of TCM symptoms of HBeAg-positive CHB patients and anti-viral effect, improve their QOL, and reduce adverse reaction of IFN-α.

关 键 词：慢性乙型肝炎 Α干扰素 逍遥散 生活质量 

分 类 号：R512.62[医药卫生—内科学]